AIDSinfo - Drug Details

A Service of The U.S. Department of Health
and Human Services

Antiretroviral Drugs

Fusion Inhibitors

Enfuvirtide (Fuzeon, T-20)

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Delavirdine (Rescriptor)

Efavirenz (Sustiva)

Nevirapine (Viramune)

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Abacavir (Ziagen)

Abacavir + Lamivudine (Epzicom)

Abacavir+Lamivudine+Zidovudine (Trizivir)

Didanosine (Videx, ddI)

Emtricitabine (Emtriva, FTC)

Emtricitabine + Tenofovir DF (Truvada)

Lamivudine (Epivir, 3TC)

Lamivudine+Zidovudine (Combivir)

Stavudine (Zerit, d4T)

Tenofovir DF (Viread)

Zalcitabine (Hivid, ddC)

Zidovudine (Retrovir, AZT, ZDV)

Protease Inhibitors (PIs)

Amprenavir (Agenerase)

Atazanavir (Reyataz)

Fosamprenavir (Lexiva, 908)

Indinavir (Crixivan)

Lopinavir+Ritonavir (Kaletra)

Nelfinavir (Viracept)

Ritonavir (Norvir)

Saquinavir (Fortovase, Invirase)

Home > Drugs > Agenerase

Amprenavir (Agenerase)

Generic Name: Amprenavir
Brand Name: Agenerase

Amprenavir, also known as Agenerase, belongs to the class of antiretroviral drugs called protease inhibitors (PIs). PIs act by blocking protease, a protein that HIV needs to make more copies of itself.

AIDSinfo Drug Record for Amprenavir

Search the Drug Database

Guidelines References to Amprenavir

	Adult and Adolescent Guidelines
	Table 12a: Antiretroviral Regimens Recommended for Treatment of HIV-1 Infection in Antiretroviral Naïve Patients
	Table 12b: Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy
	Table 13: Antiretroviral Dosing Recommendations for Patients with Renal or Hepatic Dysfunction
	Table 14: Antiretroviral Regimens or Components That Should Not Be Offered At Any Time
	Table 17: Characteristics of Protease Inhibitors (PIs)
	Table 19: Adverse Drug Reactions and Related "Black Box Warnings" in Product Labeling for Antiretroviral Agents
	Table 20: Drugs That Should Not Be Used With PI or NNRTI Antiretrovirals
	Table 21: Drug Interactions Between Antiretrovirals and Other Drugs: PIs, NNRTIs, and NRTIs
	Table 22a: Drug Effects on Blood Concentration of PIs
	Table 22b: Drug Effects on Blood Concentration of NNRTIs
	Table 23: HIV-Related Drugs with Overlapping Toxicities
	Table 27: Suggested Minimum Target Trough Concentrations for Persons with Wild-Type HIV-1
	Table 30: Preclinical and Clinical Data Concerning the Use of Antiretrovirals During Pregnancy
	Pediatric Guidelines
	Appendix: Characteristics of Available Antiretroviral Drugs
	PI Drugs - Pediatrics
	Supplement: Pediatric Antiretroviral Drug Information
	Table 10: Advantages and Disadvantages of PIs for Use in Highly Active Antiretroviral Combination Regimens
	Table 11: Recommended Antiretroviral Regimens for Initial Therapy for HIV Infection in Children
	Perinatal Guidelines
	PI Drugs - Perinatal
	Table 2: Preclinical and Clinical Data Relevant to the Use of Antiretrovirals During Pregnancy
	Table 3: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

Amprenavir News

	Important Changes in Agenerase Product Labeling
	more...

More About Amprenavir

	AIDSinfo Drug Record for Amprenavir
	MEDLINEplus Fact Sheet on Amprenavir
	Clinical Trials Using Amprenavir
	Literature Citations for Amprenavir
	more...